Literature DB >> 16144850

Urinary endothelin-1 as a marker of renal damage in sickle cell disease.

Pierre-Louis Tharaux1, Isabelle Hagège, Sandrine Placier, Michel Vayssairat, Alain Kanfer, Robert Girot, Jean-Claude Dussaule.   

Abstract

BACKGROUND: Sickle cell disease (SCD) affects the kidney by acute mechanisms as well as by insidious renal medullary/papillary necrosis, resulting in tubular defects, which increase the risk of dehydration and subsequent sickle crisis. Hypoxia has been reported to stimulate endothelin-1 (ET-1) synthesis by endothelial cells and also in the renal tubule.
METHODS: This case-control study measured ET-1 in urine as a marker of its renal synthesis in asymptomatic SCD patients. Baseline plasma and urinary ET-1 levels were measured and followed during a water deprivation study and a subsequent administration of desmopressin.
RESULTS: Urine and plasma levels of ET-1 were elevated in patients with SCD, compared with carefully matched African-French and African controls, and urine ET-1 excretion was associated with a marked urine-concentrating defect. Moreover, urinary ET-1 output was correlated with microalbuminuria in SCD patients.
CONCLUSIONS: ET-1 is known to antagonize the tubular effects of vasopressin and to promote renal scarring; increased renal production of ET-1 could produce nephrogenic diabetes insipidus and dehydration in SCD patients through a combination of fibrosis and functional resistance to vasopressin. This study provides a rationale for trials with endothelin receptor antagonists in sickle cell disease nephropathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16144850     DOI: 10.1093/ndt/gfi111

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  21 in total

1.  Endothelin-1 response to glucose and insulin among African Americans.

Authors:  Stephanie DeLoach; Yonghong Huan; Constantine Daskalakis; Bonita Falkner
Journal:  J Am Soc Hypertens       Date:  2010-08-21

2.  Pemetrexed-Induced Nephrogenic Diabetes Insipidus.

Authors:  Enrica Fung; Shuchi Anand; Vivek Bhalla
Journal:  Am J Kidney Dis       Date:  2016-05-28       Impact factor: 8.860

3.  Long-Term Endothelin-A Receptor Antagonism Provides Robust Renal Protection in Humanized Sickle Cell Disease Mice.

Authors:  Malgorzata Kasztan; Brandon M Fox; Joshua S Speed; Carmen De Miguel; Eman Y Gohar; Tim M Townes; Abdullah Kutlar; Jennifer S Pollock; David M Pollock
Journal:  J Am Soc Nephrol       Date:  2017-03-27       Impact factor: 10.121

Review 4.  Cardiomyopathy With Restrictive Physiology in Sickle Cell Disease.

Authors:  Omar Niss; Charles T Quinn; Adam Lane; Joshua Daily; Philip R Khoury; Nihal Bakeer; Thomas R Kimball; Jeffrey A Towbin; Punam Malik; Michael D Taylor
Journal:  JACC Cardiovasc Imaging       Date:  2016-02-17

5.  End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.

Authors:  Ann T Farrell; Julie Panepinto; Ankit A Desai; Adetola A Kassim; Jeffrey Lebensburger; Mark C Walters; Daniel E Bauer; Rae M Blaylark; Donna M DiMichele; Mark T Gladwin; Nancy S Green; Kathryn Hassell; Gregory J Kato; Elizabeth S Klings; Donald B Kohn; Lakshmanan Krishnamurti; Jane Little; Julie Makani; Punam Malik; Patrick T McGann; Caterina Minniti; Claudia R Morris; Isaac Odame; Patricia Ann Oneal; Rosanna Setse; Poornima Sharma; Shalini Shenoy
Journal:  Blood Adv       Date:  2019-12-10

6.  Intercellular adhesion molecule-4 and CD36 are implicated in the abnormal adhesiveness of sickle cell SAD mouse erythrocytes to endothelium.

Authors:  Marie-Marcelle Trinh-Trang-Tan; Camilo Vilela-Lamego; Julien Picot; Marie-Paule Wautier; Jean-Pierre Cartron
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

7.  Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease.

Authors:  Nathalie Sabaa; Lucia de Franceschi; Philippe Bonnin; Yves Castier; Giorgio Malpeli; Haythem Debbabi; Ariane Galaup; Micheline Maier-Redelsperger; Sophie Vandermeersch; Aldo Scarpa; Anne Janin; Bernard Levy; Robert Girot; Yves Beuzard; Christophe Leboeuf; Annie Henri; Stéphane Germain; Jean-Claude Dussaule; Pierre-Louis Tharaux
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

8.  Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis.

Authors:  Neeraj Dhaun; Pajaree Lilitkarntakul; Iain M Macintyre; Eline Muilwijk; Neil R Johnston; David C Kluth; David J Webb; Jane Goddard
Journal:  Am J Physiol Renal Physiol       Date:  2009-03-11

9.  Albuminuria correlates with hemolysis and NAG and KIM-1 in patients with sickle cell anemia.

Authors:  Dima Hamideh; Vimal Raj; Thomas Harrington; Hua Li; Emilio Margolles; Folasade Amole; Monica Garcia-Buitrago; Phillip Ruiz; Gaston Zilleruelo; Ofelia Alvarez
Journal:  Pediatr Nephrol       Date:  2014-06-03       Impact factor: 3.714

Review 10.  Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment.

Authors:  Essa Hariri; Anthony Mansour; Andrew El Alam; Yazan Daaboul; Serge Korjian; Sola Aoun Bahous
Journal:  Int Urol Nephrol       Date:  2018-01-30       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.